ED KAYE became Sarepta Therapeutics’s CEO in 2015, and guided the company through a volatile time to get the company’s first ever drug approved by the FDA. Gaining approval for the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) was critical to Sarepta’s survival and Kaye strengthened the company’s relationship with the agency to pull it off. Now Sarepta has the money to develop other Duchenne treatments. Kaye stepped aside in June. Kaye spoke with Xconomy about the Sarepta saga, his new startup, and how he thinks clinical development should be done differently.
Ed Kaye, Sarepta Therapeutics • Photography by Alex Gagne and Rythum Vinoben